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Abstract
Aminoglycosides may serve as ﬂuoroquinolone-sparing or cephalosporin-sparing agents if the clinical effectiveness of aminoglycoside
monotherapy is demonstrated. The purposes of this study were to investigate the clinical efﬁcacy of gentamicin as an initial empirical
antimicrobial agent and to evaluate the effects of gentamicin resistance on clinical outcomes in women with complicated non-obstructive
acute pyelonephritis (APN). Medical records of 1066 women with a diagnosis of APN were reviewed retrospectively. We enrolled 275
women with community-onset complicated non-obstructive APN due to Enterobacteriaceae who received gentamicin as their initial
antibiotic. Of these 275 patients, 43 had gentamicin-resistant (GM-R) Enterobacteriaceae APN, and 232 had gentamicin-susceptible (GM-S)
Enterobacteriaceae APN. The early clinical success rates were 67.4% (29/43) versus 89.7% (208/232) at 72 h in the GM-R versus the GM-S
groups (p 0.001). The overall clinical cure rate was 100% (43/43) and 98.7% (229/232) in the GM-R and GM-S groups, respectively. The
duration of hospital stay was signiﬁcantly longer in the elderly, although there were no signiﬁcant differences in the rates of early clinical
success, ﬁnal clinical cure, mortality, and time to fever clearance between the elderly and non-elderly groups. Resistance of
Enterobacteriaceae to gentamicin, haematuria and serum C-reactive protein level ≥20 mg/dL were independently associated with early
clinical failure. Gentamicin can be an effective initial antibiotic option for empirical therapy in women with community-onset complicated
APN who do not need urological interventional procedures. The use of gentamicin may contribute to a reduction of ﬂuoroquinolone or
broad-spectrum cephalosporin use in the treatment of complicated APN.
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Introduction
Patients with complicated acute pyelonephritis (APN) are a
highly heterogeneous group, with comorbidities such as
diabetes mellitus, nephrolithiasis, renal impairment, immuno-
compromised status, or other functional and anatomical
abnormalities of the urinary tract that require urological
interventions, such as surgery, percutaneous drainage, cathe-
terization and dialysis [1–3].
Most guidelines for APN have focused on premenopausal
women with uncomplicated APN, most likely as a result of the
homogeneity of the patient population and the larger research
databases available [4,5]. Elderly or diabetic women with
community-onset APN in whom no urological interventions
are necessary can be treated effectively with antimicrobial
agents alone, similar to patients with uncomplicated APN [6–8].
Gentamicin is an antibiotic option for the initial empirical
therapy of community-acquired uncomplicated APN [9–11].
However, there have been few clinical studies focusing on the
use of gentamicin as an initial empiric antibiotic therapy for
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complicated APN. In this study, gentamicin was administered
as an initial empirical antimicrobial agent in hospitalized APN
patients with complicating factors, in whom no urological
intervention was indicated. We analysed the clinical efﬁcacy of
gentamicin monotherapy.
Materials and Methods
Setting and study design
This study was retrospectively performed at the Catholic
University St Vincent’s Hospital, a 791-bed teaching hospital
in South Korea between March 2000 and February 2011.
The Institutional Review Board (IRB) of the Catholic
University St Vincent’s Hospital reviewed and approved all
protocols in this study. The IRB waived the requirement
for written, informed consent from each patient in this
study. All the data collected for this study were kept
conﬁdential.
Patient population
We included all women with community-onset complicated
APN by Enterobacteriaceae. APN was deﬁned by a fever of
≥38.0°C and the presence of pyuria on microscopic examina-
tion of the urine (>5–10 leucocytes/high-power ﬁeld) and
positive urine culture (≥105 CFU/mL for clean voided urine,
and 104 CFU/mL for catheterized urine) [9,12,13]. APN was
considered ‘complicated’ in the presence of any systemic
underlying disorder (diabetes mellitus, renal disease, kidney
transplantation, connective tissue disorder, cerebrovascular
disease, malignancy, pregnancy, immunosuppression), and/or
urinary tract abnormalities (renal stone, kidney malformation,
urological malignancy, polycystic kidney disease, vesicoureteral
reﬂux, neurogenic bladder), or age greater than 65 years
[2,14]. Patients were excluded if they were diagnosed with
APN more than 48 h after admission or if they had a urinary
catheter-related infection or a complicated obstructive APN
requiring a urological interventional procedure such as
surgery, percutaneous drainage, or catheterization for the
purpose of relieving the obstruction. Patients who did not have
radiological data consisting of computerized tomography (CT)
were also excluded.
Clinical data collection
Clinical data on age, medical history, comorbid conditions,
urinary tract conditions, urinary symptoms, relevant physical
ﬁndings, laboratory results, the duration of intravenous and
oral antibiotic administration, microbiological data, days to
defervescence, hospitalization days, mortality and adverse drug
events were collected and analysed by chart review.
Subjective symptoms of ototoxicity regarding dizziness,
vertigo, hearing impairment, medical records of ototoxicity
and laboratory evidences of acute kidney injury after genta-
micin treatment were collected. Radiological CT data were
available for all patients because abdominal CT scan was
performed as the diagnostic approach for complicated APN to
identify the presence of anatomical abnormalities or obstruc-
tive lesions.
Clinical outcome measures and deﬁnition
Treatment outcomes were assessed in terms of early clinical
success after 72 h of treatment, ﬁnal clinical outcome
(clinical cure or failure), hospitalization days, and time to
defervescence. Early clinical success at 72 h was deﬁned as
resolution of fever with improvement of urinary tract
symptoms or signs within 72 h after the start of gentamicin
monotherapy. Those patients who did not meet the criteria
of early clinical success were regarded as early clinical
failures. Clinical cure was deﬁned as the absence of
symptoms or signs at completion of therapy and/or at a
4-day to 10-day follow up, when available [15]. Clinical failure
was deﬁned as the recurrence of urinary tract symptoms
and/or signs at completion of therapy, or at a 4-day to
10-day follow up. Resolution of fever was deﬁned as an
afebrile state where the body temperature (tympanic)
remained at 37.0°C or below for 24 h or longer [9]. Time
to defervescence was deﬁned as the time from the start of
gentamicin monotherapy to an afebrile state. The tympanic
temperatures of each patient were measured every 6 h
during hospitalization.
Acute kidney injury was deﬁned as an absolute serum
creatinine increase >3 mg/dL or a relative increase in serum
creatinine >50%, in accordance with the Acute Kidney Injury
Network criteria [16]. Haematuria was deﬁned as ≥5–9 red
blood cells/high-power ﬁeld on microscopic examination of
urine.
Microbiological data
Urine specimens were plated using a 0.001-mL inoculating
loop for quantiﬁcation and incubated. Whole blood samples
taken from women with complicated APN were also
incubated. Aetiological agents were determined by
≥105 CFU/mL organisms identiﬁed on urine culture, or
isolation of urinary pathogens from blood cultures [17,18].
Species identiﬁcation and susceptibility to antimicrobial
agents were determined by means of either a semiautomated
system (Microscan; DADE Behring, West Sacramento, CA,
USA) or disc diffusion susceptibility tests according to the
criteria of the CLSI [19]. The MIC cutoff for gentamicin
resistance was ≥8 mg/L.
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Statistical methods
Results are expressed as the mean  standard deviation, or
number (percentage). Comparisons between categorical vari-
ables were assessed by using a Fisher’s exact test or the
Pearson chi-square test. Continuous variables were analysed
by the independent t test or the Mann–Whitney U test.
Logistic regression analysis was performed to evaluate the
effects of independent variables on clinical outcome. A
multivariate analysis was performed using logistic regression
to evaluate the effects of independent variables on early clinical
failure in the patients with complicated non-obstructive APN
who were treated with gentamicin monotherapy. Tests with a
probability of <0.05 were considered statistically signiﬁcant.
SPSS version 21.0 for Windows (SPSS, Inc., Chicago, IL, USA)
was used for statistical analysis.
Results
Demographic and clinical characteristics
A total of 1066 patients with a diagnosis of community-onset
APN were identiﬁed. Of the 649 patients treated by genta-
micin monotherapy, 629 had positive urine and/or blood
culture for Enterobacteriaceae. Among them, 298 women had
complicated APN. Of these, 23 were excluded because of
urological abnormalities that required urological interventions
or the absence of radiological data. Finally, 275 cases of
community-onset complicated non-obstructive APN were
enrolled and analysed (Fig. 1).
Of the 275 women, 130 women were non-elderly with
complicating factors and 145 women were elderly with or
without complicating factors. Although the frequencies of
hypertension, cerebrovascular diseases and congestive heart
failure were signiﬁcantly higher in the elderly group, the
frequencies of diabetes mellitus and urolithiasis were signif-
icantly higher in the non-elderly group. There were no
signiﬁcant differences in initial body temperature, leucocyte
counts, C-reactive protein (CRP) levels, the frequencies of
lower urinary tract infection (UTI) symptoms, ﬂank pain,
costovertebral angle tenderness, haematuria, bacteraemia,
and uropathogen resistance to gentamicin between the
elderly and non-elderly groups. There were no signiﬁcant
differences in the rates of ﬁnal clinical cure, mortality, early
clinical success, and time to fever clearance between these
groups. Median duration of hospital stay in the elderly and
non-elderly groups were 10 (8–13) and 9 (7–11) days,
respectively, signiﬁcantly longer in the elderly group (p 0.023)
(Table 1).
When the elderly group was stratiﬁed into two groups
according to the presence of other complicating factors, the
elderly group with other complicating factors had higher CRP
levels and received a lower dose of gentamicin; however, there
were no signiﬁcant differences in clinical outcomes, such as
ﬁnal clinical cure, early clinical success, mortality and duration
of hospital stay (Table 2).
Microbiological data
In the 275 cases, Escherichia coli was the most common
pathogen (258 patients; 93.8%) and non-E. coli Enterobacteri-
aceae were isolated from 17 patients (6.2%). Non-E. coli
Enterobacteriaceae comprised eight Klebsiella pneumoniae, two
Citrobacter freundii, two Citrobacter koseri, two Enterobacter
aerogenes, two Proteus mirabilis and one Enterobacter cloacae.
The antimicrobial susceptibility proﬁles of the 258 E. coli
isolates and the 17 non-E. coli isolates are shown in Table 3.
Clinical outcomes according to the presence of
gentamicin-resistant Enterobacteriaceae
Of 275 women with complicated APN, 43 patients had
gentamicin-resistant (GM-R) Enterobacteriaceae, and 232
patients had gentamicin-sensitive (GM-S) Enterobacteriaceae.
Fifteen (34.9%) of 43 patients in the GM-R group were
switched to alternative intravenous therapy. The early clinical
success rates were 32.6% (14/43) versus 62.1% (144/232) at
48 h, 67.4% (29/43) versus 89.7% (208/232) at 72 h, and 81.4%
(35/43) versus 95.7% (222/232) at 96 h in the GM-R versus
GM-S groups (p ≤0.001). Median time to defervescence was
60 h (interquartile range (IQR), 40–78) and 40 h (IQR, 30–56)
in the GM-R and GM-S groups, respectively (p <0.001)
(Fig. S1). Overall clinical cure rates were 100% (43/43) and
98.7% (229/232) in the GM-R and GM-S groups, respectively
(p >0.999). The median number of hospitalization days in the
GM-R and GM-S groups was 9 (IQR, 7–12) and 10 (IQR, 8–12),
respectively (p 0.677) (Table 4). No complications, such as
death, progression to septic shock, or renal and perirenal
abscess, occurred in either the GM-R or GM-S groups.
Microbiological outcomes were available in only 50 of 275
women at a 4–10-day follow up after completion of antimi-
crobial therapy. Microbiological cure rates were 92.1% (35/38)
and 91.7% (11/12) in the GM-R and GM-S groups, respectively,
(p >0.999) at a 4–10-day follow up.
Factors related to early clinical failure in women with
community-onset non-obstructive APN
Among 275 cases, 237 cases were placed in the early clinical
success group (at 72 h), and 38 in the early clinical failure group.
There were no signiﬁcant differences in age, proportion of
elderly patients, initial body temperature, initial leucocyte
counts, the frequencies of lower UTI symptoms, ﬂank pain or
costovertebral angle tenderness. However, the frequencies of
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1211–1218
CMI Wie et al. Gentamicin for complicated APN 1213
previous history of UTI (24.1% versus 7.9%; p 0.032), antibiotic
usage within 1 year (24.9% versus 2.6%; p 0.001), and previous
history of admission within 1 year (26.2% versus 2.6%; p 0.001)
were signiﬁcantly higher in the early clinical success group. Initial
CRP levels (18.0  8.2 versus 12.0  7.4; p <0.001) were
signiﬁcantly higher, and the frequencies of haematuria (71.1%
versus 51.1%; p 0.022) and bacteraemia (42.1% versus 19.0%;
p 0.001) were also signiﬁcantly higher in the early clinical failure
group. Furthermore, Enterobacteriaceae susceptibility to gen-
tamicin was signiﬁcantly lower in the early clinical failure group
(63.2% versus 87.8%; p <0.001). There were no signiﬁcant
differences in the prevalence of diabetes, hypertension, cere-
brovascular diseases, congestive heart failure, chronic liver
diseases, chronic lung diseases, malignancy and menopause
between the early clinical failure and clinical response groups.
Although median duration of hospital stay (11 (9.75–14) versus
9 (7–12) days; p 0.012) was longer in the early clinical failure
group, there were no signiﬁcant differences in the rates of
overall clinical cure and mortality. On mulivariate analysis,
resistance to gentamicin, haematuria, and serum CRP level
≥20 mg/dL were signiﬁcantly associated with early clinical
failure (p <0.001, p 0.012, and p 0.026) (Table S1).
649 patients with APN 
Gentamicin used as initial antibiotic
20 patients 
Other organisms isolated 
or with renal abscess  
629 patients with APN due to 
Enterobacteriaceae  
Gentamicin used as initial antibiotic
298 patients with complicated APN 
due to Enterobacteriaceae
275 patients with complicated APN due to 
Enterobacteriaceae  
who received gentamicin monotherapy 
11 patients with complicated APN 
requiring urological intervention
331 patients 
uncomplicated APN  
145 elderly women 
with complicated APN 
130 non-elderly women 
with complicated APN 
Early clinical response: 123 patients 
Early clinical failure: 22 patients 
Early clinical response: 114 patients 
Early clinical failure: 16 patients 
Overall clinical cure: 143 patients 
Overall clinical failure: 2 patients 
Overall clinical cure:  129 patients 
Overall clinical failure: 1 patient 
Antibiotics tapering  
based on the microbial susceptibility tests 
1066 patients with 
Community-onset acute pyelonephritis (APN)
417 patients 
Other antibiotics used initially  
12 patients without radiological data 
of computerized tomography 
FIG. 1. Subjects enrolment and
retrospective analysis (total acute
pyelonephritis).
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All of 275 patients had follow up at completion of therapy.
However, only 127 (46.2%) of 275 patients had follow up at 4–
10 days after the end of antimicrobial therapy. The clinical
success rates were 99.6% (236/237) versus 100% (38/38) at
completion of therapy in the early clinical success versus the
early clinical failure groups (p 0.688). The clinical success rates
were 97.2% (105/108) versus 100% (19/19) at 4–10 days after
the end of antimicrobial therapy in the early clinical success
versus the early clinical failure groups. Microbiological cure
rates were 93.6% (44/47) and 66.7% (2/3) in the early clinical
success and the early clinical failure groups, respectively,
(p 0.226) at 4- to 10-day follow up after completion of
antimicrobial therapy.
Discussion
The data in this study showed that the ﬁnal clinical cure rate
and microbiological cure rate were 98.9% and 92.0%, respec-
tively, in the gentamicin-treated women with complicated
APN. In addition, the early clinical success rates were 86.2%
and 93.5%, respectively, at 72 and 96 h after the start of
gentamicin monotherapy. In particular, 36 of 43 patients with
complicated APN due to GM-R Enterobacteriaceae had
defervescence before or without switching to alternative
intravenous antibiotics.
The overall clinical cure rate, number of hospitalization days
and mortality rate were not signiﬁcantly different between the
GM-R and GM-S groups in this study, even though APN
patients in the GM-R group had a lower early clinical response
rate than those in the GM-S group.
Although the duration of hospital stay was signiﬁcantly
longer in the elderly, there were no signiﬁcant differences in
the rates of early clinical success, ﬁnal clinical cure, mortality
and time to fever clearance between the elderly and
non-elderly women. These results suggest that gentamicin
may be an antibiotic option in elderly women with APN.
The early clinical success rates at 72 and 96 h (86.2% and
93.5%) were higher than those of women with uncompli-
cated APN due to E. coli in our previous study, in which the
early clinical success rates at 72 and 96 h were 77.0% and
90.9% [9].
TABLE 1. Demographic and clinical
characteristics of elderly and non-
elderly women with community-
onset complicated non-obstructive
acute pyelonephritis due to Entero-
bacteriaceae
Characteristics Elderly Non-elderly p-Valuea
Number of patients 145 130
Age (median, 1Q–3Q) (years) 71, 68–76 47, 36–54
Past history
Antibiotic use within 1 year 22 (15.2) 36 (27.7) 0.011
Previous urinary tract infection 17 (11.7) 43 (33.1) <0.001
Admission within 1 year 23 (15.9) 40 (30.8) 0.003
Comorbid conditions
Diabetes mellitus 49 (33.8) 90 (69.2) <0.001
Hypertension 60 (41.4) 22 (16.9) <0.001
Cerebrovascular diseases 11 (7.6) 2 (1.5) 0.022
Congestive heart failure 10 (6.9) 2 (1.5) 0.038
Chronic liver diseases 10 (6.9) 4 (3.1) 0.178
Chronic lung diseases 4 (2.8) 3 (2.3) >0.999
Malignancy 7 (4.8) 1 (0.8) 0.07
Menopause 145 (100) 57 (43.8)
Urinary tract conditions
Urolithiasis 7 (4.8) 34 (26.2) <0.001
Vesicoureteral reﬂux 2 (1.4) 7 (5.4) 0.089
Clinical and laboratory features
Initial body temperature (°C) 38.7  0.7 38.6  0.6 0.536b
Lower urinary tract infection symptoms 90 (62.1) 84 (64.6) 0.662
Flank pain 120 (82.8) 117 (90.0) 0.082
Costovertebral angle tenderness 121 (83.4) 116 (89.2) 0.165
Hematuria (≥5–9 red blood cells/HPF) 84 (57.9) 64 (49.2) 0.149
White blood cell counts (cells/mm3) 11 925  4560 11 212  4568 0.197b
White blood cells ≥20 000/mm3 of blood 8 (5.5) 5 (3.8) 0.514
C-reactive protein (mg/dL) 12.9  7.2 12.8  8.3 0.941b
C-reactive protein ≥20 mg/dL 23 (15.9) 23 (17.7) 0.685
Bacteremia 38 (26.2) 23 (17.7) 0.09
Uropathogen resistant to gentamicin 21 (14.5) 22 (16.9) 0.578
Clinical outcomes
Final clinical cure 143 (98.6) 129 (99.2) >0.999
Mortality 0 0
Early clinical success (at 72 h) 123 (84.8) 114 (87.7) 0.492
Time to fever clearance (hours), median (1Q–3Q) 41.5 (30–60) 40 (32–62) 0.983b
Hospitalization period (days), median 10 (8–13) 9 (7–11) 0.023b
Adverse drug events
Acute kidney injury 1 (0.7) 2 (1.5) 0.604
Ototoxicity 0 0
Stop due to other adverse effects 1 (0.7) 1 (0.8) >0.999
Data are shown as numbers of patients (% of total) or mean  standard deviation/median as appropriate.
aChi-square test or Fisher’s exact test.
bMann–Whitney U test.
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Current classiﬁcation based on the concept of the two main
categories, complicated and uncomplicated APN, may cause
confusion [20]. In fact, the clinical spectrum of complicated
APN ranges from severe cases with complicated APN
requiring urological interventional procedures for relieving
obstructions, to relatively mild cases that are easily treated
with ﬁrst-line antimicrobial agents. However, there are few
well-designed clinical trials examining the treatment of com-
munity-onset complicated APN [3].
Aminoglycosides are used less frequently than broad-spec-
trum cephalosporins or ﬂuoroquinolones and are usually
administered in combination with other antibiotics in the
treatment of most infectious diseases. However, aminoglyco-
side monotherapy can be used in the treatment of UTIs, as
aminoglycosides achieve a much higher renal tissue concen-
tration than other antibiotics. In recent years there have been
few adequate studies concerning the use of gentamicin in the
treatment of complicated APN.
Characteristics
Elderly with other
complicating factors
Elderly without other
complicating factors p-Valuea
Number of patients 55 90
Age (median, 1Q–3Q) (years) 70, 67–73 73, 68–77 <0.001
Past history
Antibiotic use within 1 year 8 (14.5) 14 (15.6) 0.869
Previous urinary tract infection 8 (14.5) 9 (10.0) 0.409
Admission within 1 year 8 (14.5) 15 (16.7) 0.734
Complicating factors
Diabetes mellitus 49 (89.1) 0 <0.001
Urolithiasis 7 (12.7) 0 0.001
Vesicoureteral reﬂux 2 (3.6) 0 0.142
Clinical and laboratory features
Initial body temperature (°C) 38.6  0.6 38.8  0.7 0.054b
Hematuria (≥5–9 red blood cells/HPF) 31 (56.4) 53 (58.9) 0.765
White blood cell counts (cells/mm3) 12 749  4872 11 421  4309 0.089b
White blood cells ≥20 000/mm3 of blood 4 (7.3) 4 (4.4) 0.478
C-reactive protein (mg/dL) 14.8  8.3 11.7  6.2 0.018b
C-reactive protein ≥20 mg/dL 15 (27.3) 8 (8.9) 0.003
Bacteremia 12 (21.8) 26 (28.9) 0.437
Uropathogen resistant to gentamicin 5 (9.1) 16 (17.8) 0.149
Dose of gentamicin (mg/kg per day) 4.46  0.77 4.79  0.92 0.033b
Dosing type of gentamicin Once-daily dosing Once-daily dosing
Duration of gentamicin (days) 6.98  1.41 6.61  1.56 0.151
Clinical outcomes
Final clinical cure 54 (98.2) 89 (98.9) >0.999
Mortality 0 0
Early clinical success (at 72 h) 47 (85.5) 76 (84.4) 0.869
Time to fever clearance (hours), median (1Q–3Q) 42 (30–60) 42.5 (30–63) 0.486b
Hospitalization period (days), median (1Q–3Q) 12 (8–14) 10 (8–12) 0.075b
Data are shown as numbers of patients (% of total) or mean  standard deviation/median as appropriate.
aChi-square test or Fisher’s exact test.
bMann–Whitney U test.
TABLE 2. Clinical characteristics
and outcomes in elderly women with
community-onset complicated
non-obstructive acute pyelonephritis
by the presence of other complicat-
ing factors
TABLE 3. Antimicrobial susceptibilities of Escherichia coli and non-E. coli Enterobacteriaceae isolated from women with
community-onset complicated non-obstructive acute pyelonephritis
Antibiotics
E. coli (n = 258) Non-E. coli Enterobacteriaceae (n = 17)
Resistant
(n)
Susceptible
(n)
Total
(n)
Susceptibility
(%)
Resistant
(n)
Susceptible
(n)
Total
(n)
Susceptibility
(%)
Amikacin 1 257 258 99.6 0 17 17 100
Gentamicin 43 215 258 83.3 0 17 17 100
Tobramycin 17 73 90 81.1 0 7 7 100
Ampicillin 101 50 151 33.1 6 5 11 45.5
AMOX/CLA 40 68 108 63.0 3 6 9 66.7
Piperacillin 120 77 197 39.1 3 14 17 82.4
TZP 6 249 255 97.6 0 17 17 100
Cephradine 114 140 254 55.1 3 14 17 82.4
Cefuroxme 18 239 257 93.0 1 16 17 94.1
Cetotaxime 7 250 257 97.3 1 16 17 94.1
Ceftriaxone 7 88 95 92.6 1 10 11 90.9
Ceftazidime 6 225 231 97.4 1 13 14 92.9
Cefepime 6 98 104 94.2 0 17 17 100
Imipenem 0 256 256 100 0 17 17 100
Ciproﬂoxacin 44 214 258 82.9 3 14 17 82.4
SXT 107 151 258 58.5 2 15 17 88.2
AMOX/CLA, amoxicillin/clavulanate; TZP, piperacillin/tazobactam; SXT, trimethoprim-sulfamethoxazole.
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It has been known that ototoxicity and nephrotoxicity are
the major toxicities of aminoglycosides, and once-daily amino-
glycoside dosing has been used for the purpose of reducing
toxicities. Gentamicin ototoxicity may be mainly vestibular, not
cochlear, and produce loss of balance. Gentamicin can be
vestibulotoxic in any dose, at any serum level [21–24].
However, patients with ototoxicity were not identiﬁed, and
the rate of observed nephrotoxicity was 1.1% in this study and
much lower compared with the reported rates of gentamicin
nephrotoxicity from 1.2% up to 55% in previous studies [25].
This study has a few limitations. First, this was a retrospec-
tive study. Therefore, the data for the comorbid conditions,
past history of UTI or antibiotic usage may have a relatively
low reliability. Second, we excluded patients who did not
initially receive gentamicin, and cases that required urological
interventions. These selection criteria may have biased the
study by excluding more severe cases. Third, only 50 (18.2%)
of 275 patients were microbiologically evaluable at the
follow-up visit (4–10 days post-therapy). Fourth, ototoxicity
was identiﬁed only if subjective symptoms of ototoxicity such
as vertigo, tinnitus, dizziness or hearing impairment were
found on the medical records.
In conclusion, gentamicin can be an efﬁcient and economic
antibiotic option for the initial empirical treatment of commu-
nity-onset complicated APN, especially in patients who do not
require urological procedures. The use of gentamicin may spare
the use of ﬂuoroquinolones or broad-spectrum cephalosporins
in the treatment of complicated non-obstructive APN.
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TABLE 4. Clinical outcomes of women with community-onset complicated non-obstructive acute pyelonephritis treated with
gentamicin monotherapy as initial empirical antibiotics
Characteristics
Complicated APN due to
gentamicin resistant
Enterobacteriaceae
Complicated APN due to
gentamicin-susceptible
Enterobacteriaceae p-Valuea
Number of patients 43 232
Age (median, 1Q–3Q) (years) 56, 38–72 66, 50–72 0.079b
Dose of gentamicin (mg/kg per day) 4.79  1.05 4.54  0.90 0.103b
Dosing type of gentamicin Once-daily dosing Once-daily dosing
Duration of gentamicin (days) 5.63  1.87 6.87  1.28 <0.001
Number of cases receiving alternative intravenous antibiotics 15 (34.9) 6 (2.6) <0.001
Alternative intravenous antibiotics (No. of cases)
Cefuroxime 9 5 <0.001
Amikacin 5 1 <0.001
Cefotaxime 1 0 0.156
Switch to oral antibiotics (No. of cases)
Amoxicillin 9 36 0.378
Ciproﬂoxacin 9 66 0.309
First cephalosporin 9 53 0.783
Second cephalosporin 7 35 0.842
Third cephalosporin 3 4 0.079
Trimethoprim-sulfamethoxazole 4 36 0.354
Amixicillin/calvalanate 0 1 >0.999
Duration of oral antimicrobial therapy (days) 6.70  1.93 6.95  1.24 0.417
Duration of total antimicrobial therapy (days) 14.56  2.05 13.98  0.89 0.075
Final clinical cure 43 (100) 229 (98.7) >0.999
Mortality 0 0
Time to fever clearance (hours), median (1Q–3Q) 60 (40–78) 40 (30–56) <0.001
Defervescence
Within 24 h 3 (7.0) 32 (13.8) 0.319
Within 48 h 14 (32.6) 144 (62.1) <0.001
Within 72 h 29 (67.4) 208 (89.7) <0.001
Within 96 h 35 (81.4) 222 (95.7) <0.001
Within 120 h 36 (83.7) 229 (98.7) <0.001
Hospitalization period (days), median 9 (7–12) 10 (8–12) 0.677
Adverse drug events
Acute kidney injury 0 3 (1.4) >0.999
Ototoxicity 0 0
Stop due to other adverse effects 0 2 (0.9) >0.999
Data are shown as numbers of patients (% of total) or mean  standard deviation/median as appropriate.
aChi-square test or Fisher’s exact test.
bMann–Whitney U test.
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